

Group officers:

Chair	Dr. Fernanda Herrera Lausanne – CHUV
Secretary	Dr. Judith Kroep Leiden University
Treasurer	Dr. Antonio Casado Madrid - H. San Carlos

EORTC Gynecological Cancer Group Spring Meeting

30-31 March 2023
(Lausanne, Switzerland)

Thursday 30 March 2023 (GENERAL ASSEMBLEE) CHUV, Rue du Bugnon 46, August Tissot conference room		
Time slot	Topic / Title of presentation	Speaker
14.30-15.00	WELCOME & INTRODUCTION	Chairman F. Herrera CHUV - Lausanne
	GCG group strategic plan	F. Herrera CHUV Lausanne
	Secretary report (new members)	J. Kroep Leiden University The Netherlands
	Treasurer report	A. Casado Hospital San Carlos Madrid Spain
15.00-15:30	Update from external networks GCIG	N. Ottevanger/A. Casado Marga Romeo Catalan Inst. Onc. Barcelona Spain
15.30 -16.00	Coffee break and networking	
16.00 – 17.30	New Ideas	

Group officers:

Chair	Dr. Fernanda Herrera Lausanne – CHUV
Secretary	Dr. Judith Kroep Leiden University
Treasurer	Dr. Antonio Casado Madrid - H. San Carlos

	<p>Ovarian cancer</p> <p>Evaluating the role of post-surgery systemic therapy in upfront or relapsed setting in patients with granulosa cell tumors: a randomized clinical trial. The GHOSTed trial</p> <p>Research projects in ovarian cancer and rare gynecological tumors</p> <p>Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity</p>	<p>Gloria Marquina Hospital San Carlos Madrid Spain</p> <p>Arancha Manzano Fernandez Hospital San Carlos Madrid Spain</p> <p>Manuela Undurraga Surgery Department Geneve University Hospital Switzerland</p>
	<p>Endometrial cancer</p> <p>Phase 2 study of ctDNA guided immune check point-based treatment in MSI-high/dMMR endometrial cancer. A proposal from SAKK</p> <p>Adjuvant treatment for endometrial cancer: do we really know the sequencing of chemo-radiation?"</p>	<p>Ilaria Colombo Institute of Oncology of Southern Switzerland</p> <p>Apostolos Sarivalasis CHUV Lausanne Switzerland</p>
	<p>Sarcoma</p> <p>Current therapeutic ARSENAL against advanced low grade uterine sarcoma.</p>	<p>Antonia Digklia CHUV-Lausanne</p>

Group officers:

Chair	Dr. Fernanda Herrera Lausanne – CHUV
Secretary	Dr. Judith Kroep Leiden University
Treasurer	Dr. Antonio Casado Madrid - H. San Carlos

17.30-18.00	Currently approved ideas	
	Taxol and Palbociclib in metastatic cervical cancer	Rodrigo Sanchez Bayona H. 12 de Octubre Madrid Spain
<p align="center">Friday 31st March 2023</p> <p align="center">Bugnon 25A AGORA Cancer Research Center Paternot Auditorium</p>		
Time slot	Topic / Title of presentation	Speaker
8.15 – 9.00	Breakfast at AGORA atrium <i>Meet the Y-ECI community</i>	
9.00 – 10.00	<p>Presentation of the new Y-ECI</p> <p>Proposal of the GCG – Y – ECI: Systematic review + meta-analysis of surrogacy of PFS to OS in advanced cervical and endometrial cancer. Call for proposals and presentations from Y-ECI</p>	<p>Petr Szturz Chairman Y-ECI CHUV – Lausanne</p> <p>Coordinator GCG-Y-ECI Ainhoa Madariaga 12 de Octubre Hospital Madrid Spain</p>

Group officers:

Chair	Dr. Fernanda Herrera Lausanne – CHUV
Secretary	Dr. Judith Kroep Leiden University
Treasurer	Dr. Antonio Casado Madrid - H. San Carlos

10.00 – 11.00	Welcome and Introduction Announcements and presentation of candidate group officers (i.e., chair, secretary, and treasurer) Each candidate 10-15' presentation	Chairman F. Herrera CHUV Lausanne Switzerland
11.00– 11.30	Keynote lecture: Mobilizing immunity against HGSOE (and why it has not worked so far)	Prof. George Coukos CHUV – Lausanne Switzerland
11.30 – 12.00	Keynote lecture: Novel interventions to render CAR T cells finally effective against gynecologic tumors	Prof. José Conejo García Duke University USA
12.00 – 13.00	Walking lunch and networking	
13.00 -	Presentation Results of closed trials and status of ongoing studies	
13.00 – 13.30	EORTC 1508: A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma (EORTC GCG PI: S. Banerjee) Translational research work of EORTC 1508 Denarda Dangaj Laniti	Denarda Dangaj Laniti & Eleonora Guisoni CHUV-LICR – Lausanne Switzerland

Group officers:

Chair	Dr. Fernanda Herrera Lausanne – CHUV
Secretary	Dr. Judith Kroep Leiden University
Treasurer	Dr. Antonio Casado Madrid - H. San Carlos

13.30– 14.00	EORTC 55092: Phase Ib/II of pazopanib and weekly paclitaxel / carboplatin in recurrent platin resistant ovarian carcinoma	Gloria Marquina Hospital San Carlos Madrid Spain
14.00 – 14.30	EORTC 1514: Follow-up in Gynecological Cancer Survivors: An EORTC QLQ-GCG Survivorship Protocol (EORTC QLQ PI: E. Greimel; EORTC GCG PI: A. Casado)	Eva Greimel Medical University of Graz - Austria & Antonio Casado H. San Carlos - Madrid
14.30-15.00	Short comments on 62113-55115 (EORTC/CRUK/NCI) A randomized phase II study of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma. (EORTC STBSG PI: I. Ray Coquard. EORTC GCG PI: N. Reed).	EORTC HQ team
15.00-15.30	Keynote lecture: Association of location of <i>BRCA1</i> and <i>BRCA2</i> mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis	Prof. Inthidar Labidi-Galy Geneve University Hospital Switzerland
15.30 – 16.00	Coffee break	
16.00 – 16.30	EORTC QoL OV28	V. Bjelic-Radisic Helios University Hospital Wuppertal, University Witten/Herdecke Germany.
17.00	Closing remarks	



Group officers:

Chair	Dr. Fernanda Herrera Lausanne – CHUV
Secretary	Dr. Judith Kroep Leiden University
Treasurer	Dr. Antonio Casado Madrid - H. San Carlos

This meeting is being possible thanks to the generous support of our:

Gold sponsor:



Silver sponsors:



Bronze sponsors:



And the academic support of:



Group officers:

Chair	Dr. Fernanda Herrera Lausanne – CHUV
Secretary	Dr. Judith Kroep Leiden University
Treasurer	Dr. Antonio Casado Madrid - H. San Carlos

Accommodation

Possible hotel options in Lausanne (all close to the venue or the underground M2):

<https://lausanne.hoteldespatients.ch/>

<https://alpha-palmiers-hotel-lausanne.hotel-ds.com/fr/>

<https://www.mirabeau.ch/restaurant-fr1192.html>

<https://www.movenpick.com/fr/europe/switzerland/lausanne/hotel-lausanne.html>

<https://www.hotelcontinental.ch/fr/>

How to reach to the venue from Geneva airport train station:

There is a train every 15' to Lausanne.

Most of the hotels are around Lausanne train station except Hotel des Patients which is in front of the venue.

From Lausanne train station take the M2 underground direction Croisettes, exit 5 minutes after at CHUV hospital. On Thursday we will meet at the CHUV hospital 19th floor (follow panel indications from the main entrance of the hospital, we will indicate EORTC meeting).

On Friday we will meet at the AGORA research institute in front of the hospital at the Paterno Auditorium.



Group officers:

Chair	Dr. Fernanda Herrera Lausanne – CHUV
Secretary	Dr. Judith Kroep Leiden University
Treasurer	Dr. Antonio Casado Madrid - H. San Carlos

